SO04 CYTOREDUCTIVE SURGERY AND PERIOPERATIVE INTRAPERITONEAL CHEMOTHERAPY FOR PERITONEAL CARCINOMATOSIS FOR COLORECTAL CARCINOMA

Abstract

Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) has been reported as a treatment option for patients with peritoneal carcinomatosis from colorectal carcinoma.This prospective study was to report survival outcomes and evaluate the significant prognostic factors for overall survival in 30 patients who underwent CRS and PIC.No patients were lost to follow‐up. Univariate analysis was performed to evaluate the significant prognostic factors for overall survival, defined from the time of surgery. Survival analysis was performed by using the Kaplan‐Meier method and compared using the log rank test.The median survival was 29 months (range 2–39 months). No patients died in the post‐operative period. The 1‐ and 2‐year survival rates were 72% and 64%, respectively.Six clinicopathologic factors and one treatment‐related factor for overall survival were analysed by univariant analysis. Clinicopathological factors included gender, age, timing of the surgery, histological grading, liver metastases and Peritoneal Cancer Index (PCI). Treatment‐related factors included operative duration, length of hospital stay, completeness of cytoreduction and peri‐operative morbidity. Three factors were significant for overall survival: non‐mucinous colorectal adenocarcinoma (versus mucinous, p = 0.047), PCI < 13 (versus > 13, p = 0.016), and complete cytoreduction (versus incomplete, p = 0.030).Non‐mucinous colorectal adenocarcinoma and PCI < 13 were associated with an improved survival in the 30 patients who underwent cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.